[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gjb2-gene-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gjb2-gene-mutation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100642992","phase-1-open-label-study-of-sky-gjb2-in-pediatric-subjects-with-gjb2-mediated-hearing-loss-100642992",false,"NCT07627971","Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss","A Phase 1\u002F2, Open-label, Single Dose Study of SKY-GJB2 Given as a Single Unilateral Intracochlear Administration in Pediatric Subjects With GJB2-mediated Hearing Loss","SONIX","Inclusion Criteria:\n\n* Male or female aged 9 months to 7 years at the time of gene therapy administration\n* Subjects must have at least two (biallelic) pathogenic or likely pathogenic variants in the GJB2 gene\n* Bilateral sensorineural hearing loss as assessed by ABR. Hearing loss at ≥85 dB HL for at least one of the frequencies (500-4000 Hz) in the study treatment ear.\n* Subject's parent(s)\u002Fguardian(s) provide informed consent before the initiation of study-related procedures.\n* Subject is able and willing to comply (or provide assent if old enough) will all study requirements.\n\nExclusion Criteria:\n\n* Subject has non-GJB2 mediated hearing loss including genetic, syndromic, or non-syndromic hearing loss that is not associated with GJB2 mutations.\n* Subject has autosomal dominant nonsyndromic hearing loss due to GJB2 mutation.\n* No response on ABR testing.\n* Bilateral Cochlear Implants.","ALL","9 Months","7 Years",{"count":21,"type":22},10,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Skylark Bio is conducting a study of an investigational new drug called SKY-GJB2 and its delivery device, the SKY-CAT. SKY-GJB2 is a gene therapy that is being developed to treat children who have hearing loss due to changes in the GJB2 gene (also referred to as Connexin 26). The SKY-CAT is a device that delivers the gene therapy.\n\nThe purpose of this study is to:\n\nLearn about the safety and tolerability (does not cause ongoing discomfort) of SKY-GJB2 Evaluate the efficacy of SKY-GJB2 (how well is works)",[29,30,31],"GJB2-mediated Hearing Loss","GJB2 Gene Mutation","DFNB1A",[33,34,35,36,37,38],"GJB2","Hearing Loss, Bilateral","Hearing Loss","Hearing Loss, Sensorineural","Deafness, Autosomal Recessive 1A (DFNB1A)","Connexin 26","RECRUITING","2026-06-25",{"date":42,"type":43},"2026-06-30","ACTUAL",{"date":45,"type":43},"2026-05-28",{"date":47,"type":22},"2028-06",{"name":49,"class":50},"Skylark Bio Inc.","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":78},"100470205","natural-history-in-children-up-to-16-years-with-mild-to-profound-hearing-loss-due-to-mutations-in-gjb2--otof-genes-100470205","NCT05402813","Natural History in Children up to 16 Years With Mild to Profound Hearing Loss Due to Mutations in GJB2 \u002F OTOF Genes","Longitudinal Study of the Natural History of Two Autosomal Recessive Non Syndromic Deafness (DFNB1A and DFNB9) in Children up to 16 Years of Age","Otoconex","Main Inclusion Criteria:\n\nParticipants meeting all the following main inclusion criteria will be eligible to participate in the study:\n\n* Aged ≤ 16 years on the date of signed informed consent for cohort 1 and ≤ 10 years for cohort 2;\n* With a diagnosis of non-syndromic, bilateral, mild to profound, sensorineural hearing loss (according to the American Speech Language-Hearing Association);\n* With documented genotyping results showing mutation(s) in GJB2 or OTOF genes;\n* Written informed consent as required by local regulations.\n* Either without Cochlear Implant, or with unilateral or bilateral Cochlear Implant(s)\n\nExclusion Criteria:\n\nParticipants presenting with any of the following main exclusion criteria will not be included in the study\n\n* Other type of deafness, such as unilateral deafness, persistent conductive deafness, malformation syndrome, syndromic deafness, known familial deafness linked to mutations in other genes than OTOF or GJB2;\n* Documented genotyping results showing pathogenic mutation(s) in other gene(s) than GJB2 or OTOF genes in the tested panel;\n* Unable and\u002For unwilling to comply with all the protocol requirements and\u002For study procedures.","16 Years",{"count":61,"type":22},180,"OBSERVATIONAL","The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 16 years of age.",[65,66,31,67,68,69,30],"Sensorineural Hearing Loss, Bilateral","AUNB1","Congenital Deafness","DFNB9","OTOF Gene Mutation",{"date":71,"type":43},"2026-06-01",{"date":73,"type":43},"2022-11-18",{"date":75,"type":22},"2031-06",{"name":77,"class":50},"Sensorion",1]